List view / Grid view

Anti-Cancer Therapeutics

Anti-cancer drug delivery: peptoid-coated DNA origami

29 May 2020 | By

Scientists have designed and synthesised chains of molecules for the purpose of drug delivery with a precise sequence and length to protect DNA nanostructures from degradation under biomedically relevant conditions.

Dose-adjusted chemotherapy regimen effective in Burkitt lymphoma trial

28 May 2020 | By

Researchers reveal dose-adjusted (DA) EPOCH-R chemotherapy regimen was effective across all ages of Burkitt lymphoma patients in a Phase II clinical trial.

FDA approves Lynparza (olaparib) for HRR mutated prostate cancer

21 May 2020 | By

Lynparza’s approval was based on results from a Phase III clinical trial in which it improved overall survival and progression-free survival in patients with certain prostate cancers.

FDA approves Tabrecta for treatment of metastatic non-small cell lung cancer

11 May 2020 | By

The FDA has approved Tabrecta (capmatinib) for patients with metastatic non-small cell lung cancer whose tumours have a mutation that leads to MET exon 14 skipping.

Attenuated diptheria toxin developed by researchers as novel form of drug delivery

6 May 2020 | By

A new potential platform for drug delivery has been created by researchers using attentuate diptheria toxin, which can enter cells and escape the endosome.

Novel antibody delivery method could improve precision medicine

23 April 2020 | By

Scientists have developed a protocol for encapsulating antibodies in an ultrasound-sensitive drug carrier for targeted drug delivery.

NICE recommends Vitrakvi (larotrectinib) for use on Cancer Drugs Fund

21 April 2020 | By

Larotrectinib has been given a positive opinion by NICE, following the submission of a revised price after it was previously rejected.

Novel cannabinoid formula could be used as a cancer treatment

16 April 2020 | By

The developers of the novel formulation, containing the cannabinoids CBDV and CBGA, now intend to test the clinical safety and efficacy of its anti-cancer activity.

75 percent of nanopharmaceuticals are being developed for oncology

8 April 2020 | By

A report states that three quarters of the roughly 230 nanopharmaceuticals in clinical development are for use as targeted cancer therapeutics.

Chinese ABRAXANE® supply expected to be disrupted

26 March 2020 | By

The marketing agent for China, BeiGene, announced the China National Medical Products Administration (NMPA) suspended the importation, sales and use of ABRAXANE.

Mass cytometry could reveal best cancer drug regimens for clinical trials

24 March 2020 | By

Researchers have developed a new technology that could provide real-time analysis of patient samples during clinical trials to reveal the best cancer treatment regimens.

NICE fails to recommend pembrolizumab in final draft guidance

16 March 2020 | By

The UK NICE has not found pembrolizumab cost-effective for use on the NHS, after a review of evidence collected while the drug was available via the Cancer Drugs Fund.

Flow cytometry market expected to reach $6.36 billion by 2027 12 March 2020 | By New research suggests the flow cytometry sector will grow at a CAGR of 8.2 percent due to increased adoption and expanding uses. STAR particles could be the future for treating skin conditions 11 March 2020 | By Novel particles could be incorporated into topical creams to treat dermatological conditions without systemic exposure to drugs. Gilead set to acquire Forty Seven for$4.9bn later in 2020

5 March 2020 | By

Gilead's acquisition of Forty Seven was unanimously approved by both companies' Boards of Directors, for \$95.50 per share.